Format

Send to

Choose Destination
See comment in PubMed Commons below
Phys Med Rehabil Clin N Am. 2012 Nov;23(4):821-8. doi: 10.1016/j.pmr.2012.08.003.

Novel approaches to corticosteroid treatment in Duchenne muscular dystrophy.

Author information

1
Center for Genetic Medicine Research, Children's National Medical Center, Washington, DC 20010, USA. ehoffman@cnmcresearch.org

Abstract

Although prednisone has never been formally approved for use in Duchenne muscular dystrophy (DMD) by regulatory agencies, its efficacy has been confirmed in trials dating from the 1980s. There is a strong need for optimization of both specific type of glucocorticoid (eg, prednisone, vs deflazacort or others) and the dosing regimen. Ideally an optimized regimen would maximize efficacy while minimizing side-effect profiles. A new trial, FOR-DMD, aims to address this gap in knowledge. In parallel, there has been progress in the area of "dissociative steroids," drugs that are able to better separate efficacy and side effects, providing a broader therapeutic window.

PMID:
23137739
PMCID:
PMC3606917
DOI:
10.1016/j.pmr.2012.08.003
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center